Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study-Reference-Cited by-同舟云学术

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

Published:2019-03-03 Issue:3 Volume:185 Page:492-502
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Yimer Habte¹,Melear Jason²,Faber Edward³,Bensinger William I.⁴,Burke John M.⁵,Narang Mohit⁶,Stevens Don⁷,Gunawardena Sriya⁸,Lutska Yana⁸,Qi Keqin⁹,Ukropec Jon¹⁰,Qi Ming¹¹,Lin Thomas S.⁸,Rifkin Robert M.¹²^ORCID

Affiliation:

1. Texas Oncology‐Tyler/US Oncology Research Tyler TXUSA

2. US Oncology Research Texas Oncology – Austin Midtown Austin TXUSA

3. Oncology Hematology Care Cincinnati OHUSA

4. Myeloma & Transplant Program Swedish Cancer Institute Seattle WAUSA

5. US Oncology Research Rocky Mountain Cancer Centers Aurora COUSA

6. US Oncology Research Maryland Oncology Hematology, P.A. Columbia MDUSA

7. Norton Cancer Institute Louisville KYUSA

8. Janssen Scientific Affairs, LLC Horsham PAUSA

9. Janssen Research & Development, LLC Titusville NJUSA

10. Janssen Global Medical Affairs Horsham PA USA

11. Janssen Research & Development, LLC Spring House PAUSA

12. US Oncology Research Rocky Mountain Cancer Centers Denver CO USA

Funder

Janssen Scientific Affairs, LLC

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15806

Reference29 articles.

1. CyBorD induction therapy in clinical practice

2. Can we change the disease biology of multiple myeloma?

3. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

4. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open‐label, phase 1b study;Chari A.;Blood,2017

5. Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymphocytes in autoimmune encephalitis: Pathogenesis and therapeutic target;Neurobiology of Disease;2024-10

2. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma;Cancers;2024-08-23

3. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

4. VCd vs VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG);Clinical Lymphoma Myeloma and Leukemia;2024-08

5. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-12